Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4905943 | 0.89 | POLB (0.62) | SMN1; SMN2MEN1KMT2ATP53MAPT | |
| SCHEMBL3374076 | 0.87 | MEN1 (0.57) | SMN1; SMN2MEN1KMT2ATP53MAPT | |
| SCHEMBL4907597 | 0.85 | LMNA (0.67) | SMN1; SMN2MEN1KMT2ATP53MAPT | |
| SCHEMBL2073208 | 0.85 | MAPT (0.65) | SMN1; SMN2MEN1KMT2ATP53MAPT | |
| SCHEMBL11157975 | 0.85 | MEN1 (0.62) | SMN1; SMN2MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL6311629 | 0.84 | MAPT (0.66) | SMN1; SMN2MEN1KMT2ATP53MAPT | |
| SCHEMBL7971165 | 0.84 | MEN1 (0.53) | SMN1; SMN2MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL2075250 | 0.84 | ALDH1A1 (0.72) | MEN1KMT2ATP53MAPTALDH1A1 | |
| SCHEMBL6954872 | 0.81 | MEN1 (0.53) | SMN1; SMN2MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL31578670 | 0.80 | ALDH1A1 (0.60) | MEN1KMT2ATP53MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
| EP-1765796-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | Pfizer Products Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20060229363-A1 | Substituted Heteroaryl- and Phenylsulfamoyl Compounds | HAMANAKA ERNEST S | 2006-10-12 | — | — | US | disclosed |
| WO-2006003495-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2006-01-12 | — | — | WO | disclosed |
| US-20050288340-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PFIZER INC | 2005-12-29 | — | — | US | disclosed |
| US-20030171588-A1 | 1,2-disubstituted-6-oxo-3-phenyl-piperidine-3-carboxamides and combinatorial libraries thereof | LION BIOSCIENCE AG (DE) | 2003-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229363-A1 | Substituted Heteroaryl- and Phenylsulfamoyl Compounds | PPARA, PPARG, PPARD | SMN1; SMN2 3271/4885MEN1 4859/4885KMT2A 3602/4885 |
| US-20050288340-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PPARA, PPARG, PPARD | SMN1; SMN2 3404/4885MEN1 4855/4885KMT2A 3530/4885 |
| US-20030171588-A1 | 1,2-disubstituted-6-oxo-3-phenyl-piperidine-3-carboxamides and combinatorial libraries thereof | BRD4, BICRA, HDAC6 | SMN1; SMN2 1499/4885MEN1 4019/4885KMT2A 202/4885 |
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PPARA, PPARG, PPARD | SMN1; SMN2 3404/4885MEN1 4855/4885KMT2A 3530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.